Real-World Experience of Using Dupilumab and Jak Inhibitors to Manage Pruritus in Epidermolysis Bullosa Pruriginosa
Ping‐Chen Hou, Wilson Aala, Wei‐Ting Tu, John A. McGrath, Chao‐Kai Hsu
Abstract
Epidermolysis bullosa pruriginosa (EBP) is a form of dystrophic EB associated with severe pruritus and has skewed Th2 inflammation. Our study suggests that JAK inhibitors may offer superior efficacy compared to dupilumab in treating EBP. Moreover, JAK inhibitors downregulate JAK-STAT signalling and Th1/2 cell differentiation in lesional skin while not in peripheral blood.
Topics & Concepts
DupilumabDermatologyEpidermolysis bullosaMedicineAtopic dermatitisSkin and Cellular Biology ResearchAutoimmune Bullous Skin DiseasesNail Diseases and Treatments